| General information | Literature | Expression | Regulation | Mutation | Homolog | Interaction |
Basic Information | |
|---|---|
Gene ID | 10642 |
Name | IGF2BP1 |
Synonymous | insulin-like growth factor 2 mRNA binding protein 1;IGF2BP1;insulin-like growth factor 2 mRNA binding protein 1 |
Definition | IGF-II mRNA-binding protein 1|IGF2 mRNA-binding protein 1|VICKZ family member 1|ZBP-1|coding region determinant-binding protein|insulin-like growth factor 2 mRNA-binding protein 1|zipcode-binding protein 1 |
Position | 17q21.32 |
Gene type | protein-coding |
Title | Abstract |
| melanoma | We previously reported that malignant melanomas express high levels of the mRNA binding protein coding region determinant binding protein (CRD-BP). This molecule is important for the activation of anti-apoptotic pathways, a mechanism often linked to insensitivity to therapeutics. However, it is not known whether CRD-BP plays a role in the resistance of melanomas to anti-cancer treatment. Here we demonstrate that knockdown of CRD-BP with a specific sh-RNA enhances the effect of dacarbazine, temozolomide, vinblastine, and etoposide on both primary and metastatic melanoma cell lines. CRD-BP down-regulation contributes to cell sensitization by increasing apoptosis and diminishing melanoma cell growth in response to chemotherapeutic agents. Furthermore, inhibition of CRD-BP decreases microphthalmia-associated transcription factor (MITF) expression and reintroduction of MITF partially compensates for the absence of CRD-BP. These findings suggest that high expression of CRD-BP in melanoma cells confers resistance to chemotherapy and that these CRD-BP responses are mediated, at least in part, by MITF. |